NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

JAGX

Jaguar Health Inc

Jun 20 • 04:00PM ET

2.80

Dollar change +0.02
Percentage change 0.72	%

Healthcare • Biotechnology • USA • NASD

Peers: VSTM AMRN MNOV CHRS NBIX ENTA TGTX MRSN KPTI ONCT

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-162.76	Insider Own	17.57%	Shs Outstand	1.26M	Perf Week	-26.89%
Market Cap	3.54M	Forward P/E	-	EPS next Y	-3.29	Insider Trans	0.00%	Shs Float	1.04M	Perf Month	-52.05%
Enterprise Value	37.72M	PEG	-	EPS next Q	-7.13	Inst Own	8.62%	Short Float	2.77%	Perf Quarter	-55.02%
Income	-39.73M	P/S	0.31	EPS this Y	84.85%	Inst Trans	0.11%	Short Ratio	0.20	Perf Half Y	-87.77%
Sales	11.55M	P/B	1.06	EPS next Y	83.36%	ROA	-74.37%	Short Interest	0.03M	Perf YTD	-88.91%
Book/sh	2.64	P/C	0.62	EPS next 5Y	83.11%	ROE	-423.79%	52W High	110.75 -97.47%	Perf Year	-97.04%
Cash/sh	4.50	P/FCF	-	EPS past 3/5Y	90.04% 86.61%	ROIC	-167.68%	52W Low	2.77 1.08%	Perf 3Y	-99.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.19% 15.14%	Gross Margin	62.48%	Volatility	7.11% 5.15%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	3.27	EPS Y/Y TTM	91.30%	Oper. Margin	-277.33%	ATR (14)	0.55	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	0.70	Sales Y/Y TTM	13.93%	Profit Margin	-343.92%	RSI (14)	25.47	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.08	EPS Q/Q	80.83%	SMA20	-28.38%	Beta	0.70	Target Price	38.00
Payout	-	Debt/Eq	8.98	Sales Q/Q	-5.83%	SMA50	-55.00%	Rel Volume	0.60	Prev Close	2.78
Employees	49	LT Debt/Eq	4.55	Earnings	May 15 BMO	SMA200	-84.81%	Avg Volume	143.20K	Price	2.80
IPO	May 13, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	-54.34% -21.49%	Trades		Volume	87,098	Change	0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-21	Initiated	Cantor Fitzgerald	Overweight	$5
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$2

Jun-17-25 09:00AM	Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts (ACCESSWIRE) -6.23%
07:00AM	Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream (GlobeNewswire)
Jun-11-25 10:00AM	First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs (ACCESSWIRE)
Jun-09-25 09:00AM	Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer (ACCESSWIRE) -6.40%
Jun-06-25 09:00AM	Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series (ACCESSWIRE)
08:00AM	Loading…
May-21-25 08:00AM	Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -27.05%
May-20-25 09:15AM	First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) (ACCESSWIRE)
May-16-25 07:09AM	Q1 2025 Jaguar Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.91%
03:12AM	Jaguar Health Inc (JAGX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Promising ... (GuruFocus.com)
May-15-25 02:30PM	Jaguar Health Reports First Quarter 2025 Financials (ACCESSWIRE) -10.86%
May-14-25 09:00AM	Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates (ACCESSWIRE) -6.52%
May-08-25 09:30AM	Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs (ACCESSWIRE) -20.95%
May-07-25 09:15AM	Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts (ACCESSWIRE)
Apr-30-25 08:15AM	Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients (ACCESSWIRE)
Apr-28-25 08:15AM	Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast (ACCESSWIRE)
09:00AM	Loading…
Apr-17-25 09:00AM	Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress (ACCESSWIRE)
Apr-16-25 09:50AM	Jaguar Health to present results from OnTarget study in breast cancer patients (TipRanks) +9.81%
Apr-15-25 09:30AM	Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting (ACCESSWIRE)
Apr-08-25 08:30AM	Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product (ACCESSWIRE)
Apr-04-25 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) +9.61%
Apr-01-25 04:15PM	Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
Mar-31-25 09:57AM	Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
08:00AM	Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 (ACCESSWIRE)
Mar-28-25 09:00AM	83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey (ACCESSWIRE) -7.06%
Mar-27-25 08:30AM	Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study (ACCESSWIRE)
Mar-26-25 11:00AM	Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts (ACCESSWIRE) -5.18%
09:25AM	Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now (GlobeNewswire)
Mar-25-25 07:00AM	Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now (GlobeNewswire) -10.43%
Mar-18-25 08:30AM	Jaguar Health, Inc. Announces Reverse Stock Split (ACCESSWIRE) -47.76%
04:15PM	Loading…
Mar-13-25 04:15PM	Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders (ACCESSWIRE) -6.46%
Feb-27-25 08:30AM	Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value (ACCESSWIRE) -15.59%
Feb-19-25 09:00AM	Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF) (ACCESSWIRE)
Feb-18-25 09:00AM	Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300 (ACCESSWIRE) +11.10%
07:00AM	Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now (GlobeNewswire)
Feb-13-25 09:05AM	Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts (ACCESSWIRE)
Feb-06-25 10:00AM	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference (ACCESSWIRE)
Feb-03-25 09:30AM	Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025 (ACCESSWIRE) -5.02%
Jan-29-25 08:30AM	Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO (ACCESSWIRE) -5.12%
Jan-22-25 09:00AM	Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025 (ACCESSWIRE)
Jan-10-25 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) -8.26% -7.38%
Jan-08-25 08:30AM	Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit and January 14 at Biotech Showcase (ACCESSWIRE) -7.63%
08:30AM	Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase (ACCESSWIRE)
Jan-07-25 10:00AM	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum (ACCESSWIRE) -7.81%
Dec-19-24 09:00AM	Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications (ACCESSWIRE)
Dec-18-24 10:00AM	Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder (ACCESSWIRE) -8.51%
Dec-17-24 08:30AM	FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera (ACCESSWIRE)
Dec-16-24 07:00AM	FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES (PR Newswire) -5.50%
Dec-13-24 10:00AM	Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer (ACCESSWIRE)
Dec-12-24 09:00AM	Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) (ACCESSWIRE) -23.82%
Dec-09-24 10:00AM	Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) (ACCESSWIRE) +5.65%
Dec-06-24 08:30AM	U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins (ACCESSWIRE)
Dec-05-24 12:00PM	Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine (ACCESSWIRE)
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 10:00AM	Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs (ACCESSWIRE)
Nov-25-24 10:00AM	Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference (ACCESSWIRE)
Nov-22-24 08:45AM	Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs (ACCESSWIRE) +5.62%
Nov-19-24 09:30AM	Jaguar Health Family Company Napo Therapeutics Named 'Best Pharmaceuticals Innovator of the Year - Europe' (ACCESSWIRE)
Nov-14-24 02:08AM	Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) +5.31%
Nov-13-24 08:00AM	Jaguar Health Reports Third Quarter 2024 Financial Results (ACCESSWIRE) -9.39%
Nov-11-24 08:30AM	Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates (ACCESSWIRE)
Nov-06-24 10:00AM	FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs (ACCESSWIRE)
Nov-04-24 08:30AM	Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS) (ACCESSWIRE)
Oct-29-24 10:00AM	Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting (ACCESSWIRE)
Oct-16-24 08:30AM	Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S. (ACCESSWIRE) +6.03%
Oct-11-24 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE)
Oct-10-24 10:00AM	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum (ACCESSWIRE)
Oct-09-24 06:16PM	Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ... (GuruFocus.com)
Oct-08-24 08:30AM	Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial (ACCESSWIRE)
Oct-02-24 06:52AM	Jaguars diarrhoea drug shows benefit in Phase III breast cancer subgroup (Clinical Trials Arena) +8.13%
Oct-01-24 08:30AM	Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer (ACCESSWIRE) -8.89%
Sep-26-24 10:00AM	Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors (ACCESSWIRE) +5.91%
Sep-25-24 08:30AM	Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (ACCESSWIRE)
Sep-24-24 10:00AM	Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch (ACCESSWIRE)
Sep-16-24 10:00AM	Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference (ACCESSWIRE)
Sep-10-24 10:00AM	Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care (ACCESSWIRE)
Sep-06-24 10:00AM	Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference (ACCESSWIRE)
Sep-05-24 08:30AM	Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs (ACCESSWIRE)
Sep-04-24 10:00AM	New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones (ACCESSWIRE)
Aug-27-24 10:00AM	Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) (ACCESSWIRE)
Aug-20-24 10:00AM	Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award (ACCESSWIRE)
Aug-19-24 10:00AM	Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) (ACCESSWIRE)
Aug-13-24 08:00AM	Jaguar Health Reports Second Quarter 2024 Financial Results (ACCESSWIRE) -10.83%
Aug-12-24 10:00AM	REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trials Clinically Meaningful Results in Breast and Lung Cancer Patients (ACCESSWIRE) +8.11%
Aug-05-24 10:18AM	Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial's Clinically Meaningful Results (ACCESSWIRE)
Aug-02-24 10:00AM	Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy (ACCESSWIRE)
Aug-01-24 09:00AM	Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting (ACCESSWIRE)
Jul-31-24 10:00AM	Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) (ACCESSWIRE) +6.03%
Jul-23-24 12:13PM	Jaguar Health shares slump following Phase III Mytesi failure (Clinical Trials Arena) -58.78%
08:00AM	Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer (ACCESSWIRE)
Jul-18-24 10:30AM	Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning (ACCESSWIRE)
Jun-26-24 08:30AM	Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement (ACCESSWIRE)
Jun-21-24 04:15PM	Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders (ACCESSWIRE)
Jun-12-24 08:30AM	Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 (ACCESSWIRE)
Jun-07-24 04:15PM	Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) -5.25% +9.42%
May-29-24 08:30AM	Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia (ACCESSWIRE) +8.19%
May-28-24 08:30AM	Investigator-Initiated Trial of Jaguar Health's Crofelemer Yields Positive Results for Functional Diarrhea (ACCESSWIRE) -12.96%
May-23-24 08:30AM	Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product (ACCESSWIRE) -33.26%
May-20-24 10:25AM	Red Lobster Bankruptcy: What Happened to the Popular Seafood Chain? (InvestorPlace) -34.78%

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JAGX

Jaguar Health Inc

Upgrade your FINVIZ experience